ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,548,009 | -49.2% | 1,660,520 | -2.7% | 0.00% | -100.0% |
| Q2 2023 | $36,512,145 | -41.3% | 1,706,175 | +11.0% | 0.00% | -50.0% |
| Q1 2023 | $62,152,357 | -12.2% | 1,536,903 | +1.0% | 0.00% | 0.0% |
| Q4 2022 | $70,812,232 | -7.6% | 1,522,189 | +3.1% | 0.00% | 0.0% |
| Q3 2022 | $76,609,000 | +6.9% | 1,476,910 | -2.6% | 0.00% | 0.0% |
| Q2 2022 | $71,694,000 | -36.6% | 1,516,689 | -4.6% | 0.00% | -33.3% |
| Q1 2022 | $113,122,000 | -7.0% | 1,589,224 | -2.3% | 0.00% | 0.0% |
| Q4 2021 | $121,586,000 | +18.9% | 1,625,909 | -9.7% | 0.00% | 0.0% |
| Q3 2021 | $102,278,000 | +25.1% | 1,800,363 | -3.1% | 0.00% | +50.0% |
| Q2 2021 | $81,727,000 | -12.7% | 1,857,019 | -2.2% | 0.00% | -33.3% |
| Q1 2021 | $93,642,000 | +23.5% | 1,898,674 | +5.4% | 0.00% | +50.0% |
| Q4 2020 | $75,804,000 | -3.8% | 1,800,579 | +4.6% | 0.00% | -33.3% |
| Q3 2020 | $78,782,000 | -7.2% | 1,720,890 | +1.8% | 0.00% | 0.0% |
| Q2 2020 | $84,895,000 | -2.3% | 1,690,797 | +0.0% | 0.00% | -25.0% |
| Q1 2020 | $86,930,000 | -17.1% | 1,690,260 | -0.4% | 0.00% | 0.0% |
| Q4 2019 | $104,885,000 | +3.5% | 1,697,729 | +0.6% | 0.00% | 0.0% |
| Q3 2019 | $101,345,000 | -25.9% | 1,686,848 | +4.1% | 0.00% | -20.0% |
| Q2 2019 | $136,751,000 | -11.8% | 1,620,650 | -0.2% | 0.01% | -16.7% |
| Q1 2019 | $155,056,000 | +43.5% | 1,623,291 | +6.4% | 0.01% | +20.0% |
| Q4 2018 | $108,075,000 | -11.4% | 1,525,834 | +6.9% | 0.01% | 0.0% |
| Q3 2018 | $121,934,000 | -4.0% | 1,426,791 | +30.1% | 0.01% | 0.0% |
| Q2 2018 | $127,075,000 | +81.3% | 1,096,417 | +26.5% | 0.01% | +66.7% |
| Q1 2018 | $70,100,000 | +45.4% | 866,391 | +5.4% | 0.00% | +50.0% |
| Q4 2017 | $48,216,000 | +23.0% | 821,687 | -1.9% | 0.00% | 0.0% |
| Q3 2017 | $39,198,000 | +28.6% | 837,563 | -1.1% | 0.00% | 0.0% |
| Q2 2017 | $30,475,000 | +24.9% | 847,021 | +6.9% | 0.00% | +100.0% |
| Q1 2017 | $24,399,000 | -1.5% | 792,165 | +7.2% | 0.00% | 0.0% |
| Q4 2016 | $24,761,000 | +33.5% | 739,158 | +6.1% | 0.00% | 0.0% |
| Q3 2016 | $18,543,000 | +29.3% | 696,877 | +7.1% | 0.00% | 0.0% |
| Q2 2016 | $14,345,000 | -22.7% | 650,560 | +3.0% | 0.00% | 0.0% |
| Q1 2016 | $18,547,000 | -8.8% | 631,489 | +2.5% | 0.00% | 0.0% |
| Q4 2015 | $20,340,000 | -92.3% | 616,028 | -92.0% | 0.00% | -90.0% |
| Q3 2015 | $265,068,000 | +1813.7% | 7,686,826 | +2396.7% | 0.01% | +900.0% |
| Q2 2015 | $13,851,000 | +59.0% | 307,882 | +8.2% | 0.00% | 0.0% |
| Q1 2015 | $8,711,000 | -35.0% | 284,476 | +8.0% | 0.00% | 0.0% |
| Q4 2014 | $13,396,000 | +39.7% | 263,446 | +8.7% | 0.00% | 0.0% |
| Q3 2014 | $9,587,000 | +23.7% | 242,260 | +34.7% | 0.00% | 0.0% |
| Q2 2014 | $7,749,000 | +15.6% | 179,910 | +7.3% | 0.00% | 0.0% |
| Q1 2014 | $6,703,000 | +400.2% | 167,631 | +241.3% | 0.00% | – |
| Q4 2013 | $1,340,000 | +90.9% | 49,119 | +60.4% | 0.00% | – |
| Q3 2013 | $702,000 | +28.6% | 30,630 | -0.6% | 0.00% | – |
| Q2 2013 | $546,000 | – | 30,826 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |